Imatinib Therapy for Patients with Chronic Myelogenous Leukemia

  title={Imatinib Therapy for Patients with Chronic Myelogenous Leukemia},
  author={D. DeAngelo and J. Ritz},
  journal={Clinical Cancer Research},
  pages={1 - 3}
  • D. DeAngelo, J. Ritz
  • Published 2004
  • Medicine, Biology
  • Clinical Cancer Research
  • Chronic myelogenous leukemia (CML) is a clonal hematopoietic disorder characterized by the reciprocal translocation involving chromosomes 9 and 22. As a result of this translocation, a novel fusion gene, BCR-ABL is created and the constitutive activity of this tyrosine kinase plays a central role in 
    9 Citations
    The transformative journey of chronic myeloid leukemia
    • 1
    • PDF
    MicroRNA 30a Mediated Autophagy and Imatinib Response in Egyptian Chronic Myeloid Leukemia Patients
    Study of Imatinib Cardiotoxicity In Adult Male Rabbits
    • 3
    A review on various targeted anticancer therapies
    • 58
    • Highly Influenced


    Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia.
    • 1,988
    Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia.
    • 3,235
    • PDF
    Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia.
    • 1,240
    • PDF
    Detection of a potent humoral response associated with immune-induced remission of chronic myelogenous leukemia.
    • 140
    • PDF
    Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr–Abl positive cells
    • 3,461
    • PDF
    Quantitative Monitoring of BCR / ABL Transcript During STI-571 Therapy
    • 14